FIGURE 4.

Effects of dasatinib and/or z‐VAD‐fmk on the expression of procaspase‐9, DR‐5 and PARP and DNA fragmentation in YD‐38 cells. A, YD‐38 cells were treated without or with dasatinib (10 μM) for the indicated times. At each time point, whole‐cell lysates were prepared and analysed by Western blotting. B, YD‐38 cells were pre‐treated for 1 h with a pan‐caspase inhibitor z‐VAD‐fmk (50 μM) and then treated with or without dasatinib (10 μM) in the absence or presence of z‐VAD‐fmk for an additional 8 h. The genomic DNA was extracted and analysed on 1.7% agarose gels for DNA fragmentation. Each picture is representative of three independent experiments